Joint safety alert in relation to appropriate doses of oestrogen and progestogen provided to women experiencing symptoms of menopause
This safety alert from April 2023 has been produced in response to questions raised about appropriate doses of oestrogen and progestogen provided to women experiencing symptoms of menopause. The alert has been produced conjointly by the British Menopause Society, Faculty of Sexual & Reproductive Healthcare, Royal College of General Practitioners, Royal College of Obstetricians & Gynaecologists, Society for Endocrinology and the Royal College of Nursing Women’s Health Forum.
The alert discusses increasing reports of women being initiated on high doses of oestrogen which exceed the product licenses, not in line with any clinical guidelines. It emphasises the importance of patients being managed safely within established guidelines set out by organisations like the National Institute for Health and Care Excellence (NICE) and the MHRA, and discusses the correct way to prescribe oestrogen, as well as progestogen.
To read the alert, please visit the British Menopause Society website.